Share this video  

ASCO 2023 | HER2-targeting ADCs for urothelial carcinoma

Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, discusses HER2 as an antibody-drug conjugate (ADC) target for urothelial carcinoma (UC). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.